Oncology dominates CRISPR landscape: GlobalData
Oncology accounts for 30 per cent of all active CRISPR drugs
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
CRISPR
Innovations paving the way for drug discovery of rare diseases
Sanjay Vyas, Executive VP and MD, Parexel examines the challenges associated with rare diseases in India, and emphasises on the…
Vertex Pharma poised to dominate global gene therapy market with first CRISPR approval: GlobalData
The global cell and gene therapy market is expected to reach $80 billion in 2029, with a high CAGR of 51.6 per cent between 2023…
Verve’s gene-editing therapy trial to lower cholesterol levels opens doors for use in CVDs:…
PCSK9 inhibitors, like VERVE-101, currently holds 20 per cent market share in the acute coronary syndrome market. PCSK9 inhibitors…
Tel Aviv University develops novel lipid nanoparticle-based delivery system to destroy cancer cells
The system, called CRISPR-LNPs, carries a genetic messenger (messenger RNA), which encodes for the CRISPR enzyme Cas9 that acts as…
Novartis collaborates with Intellia Therapeutics and Caribou Biosciences
To explore making medicines and drug discovery tools with CRISPR genome editing technology